Clinical TopicsImmune/Lymphatic SystemInfection PreventionInfectious DiseasesNewsOncologyWeb Exclusives

Drugs Today – January 2008

Breast cancer drug approved
The U.S. Food and Drug Administration has approved Ixempra (ixabepilone) to treat advanced breast cancer that hasn’t responded to treatment with three other types of chemotherapy. The drug was also approved for use with Xeloda (capecitabine) in women with breast cancer that has spread to other parts of the body.
Gardasil vaccine for older women
Currently used to prevent cervical cancer in girls and women ages 9 to 26, Gardasil [quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine] may also provide protection for women up to age 45. Merck, the maker of the vaccine, directed a study of 3,800 women ages 24 to 45, in which Gardasil prevented 91% of cases of persistent infection, minor cervical abnormalities, precancers, and genital warts caused by four strains of the sexually transmitted human papillomavirus.
Combination eyedrops for glaucoma
The U.S. Food and Drug Administration has approved Combigan eyedrops to slow the progression of glaucoma. The combination drug contains brimonidine tartrate (an alpha-adrenergic receptor agonist) and timolol maleate (a beta-
adrenergic receptor blocker). Combigan, which helps reduce elevated intraocular pressure in patients with glaucoma or ocular hypertension, may be used as adjunctive or replacement therapy.

Marketing of Trasylol suspended
At the request of the U.S. Food and Drug Administration, Bayer Pharmaceuticals has agreed to a marketing suspension of Trasylol (aprotinin injection), pending a review of preliminary results from a Canadian study suggesting an increased risk of death. The drug is used to control bleeding during heart surgery.

The views and opinions expressed here are those of the author and do not necessarily reflect the opinions or recommendations of the American Nurses Association, the Editorial Advisory Board members, or the Publisher, Editors and staff of American Nurse Journal. This has not been peer reviewed.

cheryl meeGet your free access to the exclusive newsletter of American Nurse Journal and gain insights for your nursing practice.

NurseLine Newsletter

  • Hidden

*By submitting your e-mail, you are opting in to receiving information from Healthcom Media and Affiliates. The details, including your email address/mobile number, may be used to keep you informed about future products and services.

Test Your Knowledge

Which of the following statements about traumatic hyphema is true?

More Perspectives